Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncothyreon has enrolled the first patient in a Phase 2 trial evaluating PX-866 in patients with glioblastoma multiforme that has recurred during or following primary therapy.
Subscribe to our email newsletter
The single-arm screening Phase 2 trial is being conducted at seven centres across Canada and will enroll up to 30 patients whose brain tumour is in first relapse during or following primary therapy.
The primary endpoint of the trial is a combination of objective response rate and early progression.
PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.